Outcomes with intensive treatment for acute myeloid leukemia : an analysis of two decades of data from the HARMONY Alliance
Sobas, Marta Anna (Wroclaw Medical University)
Turki, Amin (Ruhr-Universität Bochum)
Villaverde Ramiro, Ángela (Instituto de Investigación Biomédica de Salamanca)
Hernández-Sánchez, Alberto (Hospital Universitario de Salamanca)
Martínez Elicegui, Javier (Instituto de Investigación Biomédica de Salamanca)
González, Teresa (Instituto de Investigación Biomédica de Salamanca)
Melchor, R.A. (Hospital Universitario de Salamanca)
Abáigar, María (Instituto de Investigación Biomédica de Salamanca)
Tur, L. (GMV Innovating Solutions)
Dall'Olio, Daniele (IRCCS Istituto delle Scienze Neurologiche di Bologna)
Sträng, E. (Humboldt-Universität zu Berlin)
Tettero, JM. (Vrije Universiteit Amsterdam)
Castellani, Gastone (Università di Bologna)
Benner, Axel (German Cancer Research Center (DKFZ))
Döhner, Konstanze (University Hospital of Ulm (Alemanya))
Thiede, Christian (University Hospital Dresden)
Metzeler, Klaus H. (University of Leipzig Medical Center)
Haferlach, T. (MLL Munich Leukemia Laboratory)
Damm, Frederik (German Cancer Research Center (DKFZ))
Ayala, Rosa (Hospital Universitario 12 de Octubre (Madrid))
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Mills, Ken (Queen's University Belfast)
Sierra, Jorge (Institut de Recerca Sant Pau)
Lehmann, Sylvain (Uppsala University Hospital)
Della Porta, Matteo Giovanni (Humanitas University)
Mayer, Jiří (Masaryk University)
Reinhardt, Dirk (University Duisburg-Essen)
Villoria Medina, Rubén (GMV Innovating Solutions)
Schulze-Rath, Renate (Bayer AG)
Barbus, Martje (AbbVie Deutschland GmbH & Co KG)
Hernández Rivas, Jesús María (Hospital Universitario de Salamanca)
Huntly, Brian (University of Cambridge)
Ossenkoppele, G. (Amsterdam University Medical Center)
Döhner, Hartmut (University Hospital of Ulm (Alemanya))
Bullinger, Lars (German Cancer Research Center (DKFZ))
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2025
Resum:	Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcomes of patients with acute myeloid leukemia (AML). However, even before these innovations, outcomes with intensive chemotherapy had improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5,359 AML patients, we compared the impact of intensive induction therapy on outcome over four consecutive 5-year calendar periods from 1997 to 2016. During that time, the 5-year survival of AML patients improved significantly, also across different genetic risk groups. In particular, the 60-day mortality rate dropped from 13. 0% to 4. 7% over time. The independent effect of calendar periods on outcome was confirmed in multivariate models. Improvements were documented both for patients <60 and ≥60 years old, and in those treated with and without consolidating allogeneic hematopoietic stem cell transplantation (alloHCT). While survival of AML elderly patients remains poor, patients ≥60 years old overall have a 20% survival benefit at 5 years if they receive an alloHCT. While further outcome improvement in intensively treated AML patients will likely be driven by targeted treatment approaches, this pan-European HARMONY dataset can serve as a multicenter comparator for future studies.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Europe ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute ; Male ; Middle Aged ; Prognosis ; Treatment Outcome ; Young Adult
Publicat a:	Haematologica, Vol. 110 Núm. 5 (may 2025) , p. 1126-1140, ISSN 1592-8721

DOI: 10.3324/haematol.2024.285805
PMID: 39506894

15 p, 4.3 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats